Easttop(SZ:002889) Mei Ri Jing Ji Xin Wen·2025-10-24 11:24Group 1 - The core viewpoint of the article highlights the financial performance of Dongfang Jiasheng in Q3 2025, showing a revenue increase but a decline in net profit and earnings per share [1] - Dongfang Jiasheng reported a revenue of approximately 2.898 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 12.63% [1] - The net profit attributable to shareholders was approximately 141 million yuan, reflecting a year-on-year decrease of 21.2% [1] - The basic earnings per share were reported at 0.3757 yuan, which is a decrease of 21.24% compared to the previous year [1] Group 2 - As of the report, Dongfang Jiasheng has a market capitalization of 5.7 billion yuan [2] - The article discusses the broader context of the biopharmaceutical market, noting that China’s innovative drugs have generated 80 billion USD in overseas licensing this year [2] - The conversation with Lu Gang, a partner at Chuangdong Investment, indicates a contrast between the hot secondary market for biopharmaceuticals and the cooling fundraising environment in the primary market [2]